Aurinia Pharmaceuticals Inc.
AUPH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001600620
In the last 90 days, Aurinia Pharmaceuticals Inc. insiders filed 0 open-market purchases and 2 sales; 282 institutions reported holding it in 13F filings for Q2 2026, worth $1.34B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $546.4K in total
- 2
- 13F holdersQ2 2026, +25 vs. previous quarter
- 282
- 13F valueReported value at the end of Q2 2026
- $1.34B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding AUPH, Q2 2026
No superinvestor reported holding AUPH at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Aurinia Pharmaceuticals Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 11, 2026 (view filing)4:26 PM ET | Sep 10 | 1 day | Robertson Stephen P.Chief Legal Officer | SSale | −11.9K | $15.95 | −$190.4K | −2.0%588.8K after | |
| Aug 25, 2026 (view filing)9:29 PM ET | Aug 21 | 4 days | Robertson Stephen P.Chief Legal Officer | SSale | −21.0K | $16.97 | −$355.9K | −3.4%600.8K after | |
| Jun 2, 2026 (view filing)9:54 PM ET | May 29-Jun 2 | 4 days | Tang Kevin C and 1 otherChief Executive Officer | PPurchase | +814.6K | $15.29 | +$12.5M | +6.7%13.0M after | 5 lots |
| Mar 3, 2026 (view filing) | Feb 27-Mar 3 | 4 days | Tang Kevin CDirector | PPurchase | +900.0K | $14.10 | +$12.7M | +7.9%12.2M after | 6 lots |
| Aug 5, 2025 (view filing) | Aug 1 | 4 days | Keenan GregChief Medical Officer | SSale | −20.0K | $10.50 | −$210.0K | −13.0%133.5K after | |
| Aug 5, 2025 (view filing) | Aug 1-5 | 4 days | Tang Kevin CDirector | PPurchase | +1.30M | $10.45 | +$13.6M | +13.0%11.3M after | 3 lots |
| Mar 7, 2025 (view filing) | Mar 7 | Same day | Keenan GregChief Medical Officer | SSale | −8.30K | $8.23 | −$68.4K | −5.1%153.5K after | |
| Mar 4, 2025 (view filing) | Mar 3-4 | 1 day | Greenleaf PeterChief Executive Officer | SSale | −360.5K | $7.96 | −$2.87M | −16.8%1.79M after | 2 lots |
| Mar 4, 2025 (view filing) | Mar 3 | 1 day | Keenan GregChief Medical Officer | SSale | −12.2K | $8.00 | −$97.9K | −7.0%161.8K after | |
| Mar 4, 2025 (view filing) | Mar 3-4 | 1 day | Miller Joseph MChief Financial Officer | SSale | −118.0K | $7.96 | −$939.6K | −17.0%577.4K after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Aurinia Pharmaceuticals Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Tang Capital Management LLC | 13,044,106 | $221.4M | 10.05% | +814,606+6.7% | Added |
| BlackRock, Inc. | 8,193,085 | $139.0M | 0.00% | +347,564+4.4% | Added |
| Goldman Sachs Group Inc | 5,619,401 | $95.4M | 0.01% | +4,185,893+292.0% | Added |
| NEA Management Company, LLC | 3,969,834 | $67.4M | 4.24% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 3,467,514 | $58.8M | 0.04% | +38,809+1.1% | Added |
| Arrowstreet Capital, Limited Partnership | 3,264,062 | $55.4M | 0.02% | −20,306−0.6% | Reduced |
| State Street Corp | 2,589,615 | $43.9M | 0.00% | +62,516+2.5% | Added |
| Morgan Stanley | 2,308,244 | $39.2M | 0.00% | +75,696+3.4% | Added |
| Marshall Wace, LLP | 2,044,007 | $34.7M | 0.03% | +169,410+9.0% | Added |
| Geode Capital Management, LLC | 1,701,152 | $28.9M | 0.00% | +165,143+10.8% | Added |